Key takeaways
- A landmark EY-Parthenon survey of nearly 15,000 consumers shows 54% of GLP-1 patients use the drugs for weight loss, officially eclipsing diabetes care.
- The massive shift is driving structural changes across US industries, including smaller grocery portion sizes, wardrobe refreshes, and increased fitness spending.
- Wider adoption among younger and lower-income consumers is supported by federal pricing agreements bringing brand-name cash prices down to $150–$350 monthly.
- Researchers at Wharton are initiating a first-of-its-kind study to evaluate if GLP-1s can curb impulsive behaviors like gambling and luxury retail spending.
What happened
A new consumer survey reveals that a majority of Americans taking GLP-1 medications are now using them for weight loss rather than for type 2 diabetes or other medical conditions. The market research firm EY-Parthenon reported that approximately 54% of patients taking semaglutide drugs, such as Wegovy or Ozempic, use them primarily for weight management. This milestone marks the first time weight loss has overtaken all other medical reasons as the primary driver of GLP-1 usage in the United States.
Why it matters
For online GLP-1 buyers, this shift signals a profound transformation in how these medications are perceived, prescribed, and paid for. What began as a highly specialized class of diabetes treatments has officially transitioned into a mainstream wellness and weight-management tool. This massive influx of lifestyle and weight-loss buyers is driving retail, apparel, and food markets to adapt to changing consumer behaviors.
As demand shifts from chronic disease management to broad-scale weight loss, more buyers are bypassing traditional clinical channels. Instead, they are turning to cash-pay telehealth platforms to secure prescriptions, accelerating the expansion of online care networks.
What the data says
The data, collected by EY-Parthenon in a survey of nearly 15,000 people—including 3,602 current or former GLP-1 users—highlights how rapidly the medication is altering daily habits:
- Dietary Shifts: 63% of GLP-1 users have decreased their consumption of sweet snacks, and 57% report eating fewer salty snacks, choosing healthier, protein-enhanced foods instead.
- Retail Adaptation: Retailers and manufacturers are redesigning store shelves to feature GLP-1-diet-specific products and smaller portion sizes.
- Wardrobe Refreshes: 72% of GLP-1 users reported sizing down in clothing, with 46% switching apparel brands entirely due to rapid weight loss.
- Physical Wellness: Roughly half of the surveyed users increased their personal spending on fitness services, such as gym memberships.
The report also underscores that GLP-1s are reaching a broader, more diverse demographic—including younger, lower-income, and male consumers. This widening demographic is largely fueled by improved affordability. Under a federal agreement with manufacturers Eli Lilly and Novo Nordisk, the cash price of brand-name Ozempic and Wegovy was lowered to between $150 and $350 per month, down from the original retail price of roughly $1,000. Additionally, the Medicare GLP-1 Bridge program now allows eligible beneficiaries to access these medications for $50 a month.
How it compares
The explosive growth of weight-loss buyers directly impacts how patients choose between brand-name medications and alternative online provider options. For years, the primary choice for patients was securing coverage for brand-name GLP-1s through employer-sponsored insurance. However, as documented in our look at how a JAMA study links surgery to lower downstream costs than GLP-1s, insurance companies are increasingly squeezing GLP-1 coverage due to high long-term costs.
Faced with insurance denials, the modern weight-loss buyer must choose between paying the negotiated $150 to $350 brand-name cash price or exploring compounding pharmacies through digital health clinics. For comparison:
- Brand-Name Cash Price: Brand Wegovy or Zepbound costs between $150 and $350 per month under recent pricing agreements, but availability can still be limited by manufacturer shortages.
- Compounded Semaglutide/Tirzepatide: Online telehealth platforms offer compounded alternatives starting between $150 and $299 per month. These options bypass insurance requirements entirely but introduce different clinical considerations. For instance, as explored in our coverage of how a JAMA study reveals B12 is coformulated in a majority of compounded GLP-1s, buyers often navigate custom formulations that contain additives like Vitamin B12.
Furthermore, as weight loss becomes the dominant reason for use, telehealth platforms have streamlined their online consultations to cater to this demographic, making it easier than ever to compare plans on our providers directory.
How this fits the bigger picture
The dominance of weight-loss users represents a permanent structural change in the American economy. Major brands are already pivoting to capture this new demographic's spending power. For example, in our report on how L'Oreal targets GLP-1 skin sagging, we highlighted how even beauty and skincare conglomerates are formulating specialized products to address the rapid physical changes associated with GLP-1 weight loss, adding new dimensions to patient budgets.
This transition also changes how telehealth platforms market these therapies. Because GLP-1s affect the brain's reward system, researchers are now looking beyond weight loss to other behavioral conditions. In our analysis of how telehealth platforms launch off-label GLP-1 plans for addiction, we noted that providers are already leveraging these neurological effects to market the drugs for impulse control. This aligns closely with a new, first-of-its-kind study by the Wharton School of the University of Pennsylvania, which is currently examining whether GLP-1s can reduce non-food temptations, such as risky financial decisions, gambling, and luxury retail spending.
For consumers navigating this rapidly shifting marketplace, comparing telehealth options on our compare page has become an essential step in finding safe, affordable, and reliable clinical care.
What happens next
As weight-loss usage continues to outpace all other medical applications, several key market developments are on the horizon:
- Retail and CPG Adjustments: Food manufacturers and grocery chains will continue expanding product lines featuring smaller portions and protein-heavy formulations to match the shrinking appetites of the American consumer.
- Wharton Study Readouts: The Wharton School's clinical investigation into GLP-1s and impulsive spending habits will provide new data on how these medications alter consumer decision-making and addiction-related behaviors.
- Policy and Price Monitoring: Industry analysts will watch whether the current $150 to $350 price cap for brand-name drugs remains stable, and whether more employers choose to drop or restrict GLP-1 coverage in response to the massive wave of lifestyle users.
CompareRx provides factual information for educational purposes and does not offer medical advice. Always consult a licensed healthcare professional before starting or changing any medication regimen.